Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
STSA
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q4.20
N/A
-0.72
vs -0.62
Q1.21
N/A
-0.48
vs -0.68
Q2.21
N/A
-0.38
vs -0.65
Q3.21
N/A
-0.42
vs -0.69
Q4.21
N/A
-0.49
vs -0.72
Q1.22
N/A
-0.49
vs -0.48
Q2.22
N/A
-0.52
vs -0.38
Q3.22
N/A
-0.48
vs -0.42
Q4.22
N/A
-0.70
vs -0.49
Q1.23
N/A
-0.31
vs -0.49
Sales Growth
YoY
Current
Estimates
Q4.20
NA
NA vs NA
Q1.21
NA
NA vs NA
Q2.21
NA
NA vs NA
Q3.21
NA
NA vs NA
Q4.21
NA
NA vs NA
Q1.22
NA
NA vs NA
Q2.22
NA
NA vs NA
Q3.22
NA
NA vs NA
Q4.22
NA
NA vs NA
Q1.23
NA
NA vs NA
Return on Equity
QoQ
Q4.20
-17%
-0.17
vs -0.15
Q1.21
-8%
-0.08
vs -0.17
Q2.21
-9%
-0.09
vs -0.08
Q3.21
-12%
-0.12
vs -0.09
Q4.21
-15%
-0.15
vs -0.12
Q1.22
-18%
-0.18
vs -0.15
Q2.22
-22%
-0.22
vs -0.18
Q3.22
-22%
-0.22
vs -0.22
Q4.22
+11%
0.11
vs -0.22
Q1.23
-26%
-0.26
vs 0.11
Institutionnal Ownership
QoQ
Q4.20
48
48
vs 46
4%
Q1.21
61
61
vs 48
27%
Q2.21
58
58
vs 61
-5%
Q3.21
47
47
vs 58
-19%
Q4.21
32
32
vs 47
-32%
Q1.22
33
33
vs 32
3%
Q2.22
31
31
vs 33
-6%
Q3.22
46
46
vs 31
48%
Q4.22
36
36
vs 46
-22%
Q1.23
33
33
vs 36
-8%
Forecast
2025-Revenue
2025-EPS
2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
N/A(N/A)
Number of analyst
N/A
Last analyst upgrade/downgrade
SVB Leerink
downgradePrevious: Outperform
2022-11-15
Now: Market Perform
SVB Leerink
upgradePrevious: Not converted
2022-10-10
Now: Outperform
Quote Panel
Key Metrics
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
Relative Strenght
42
Volume Buzz
65%
Earning Acce
No
Dist 52w H.
86%Relative Strength
STSA
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
